Unknown

Dataset Information

0

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.


ABSTRACT: Subcutaneous peginterferon beta-1a provided clinical benefits at Year 1 (placebo-controlled period) of the 2-Year Phase 3 ADVANCE study in relapsing-remitting multiple sclerosis (RRMS). Here we report the effect of peginterferon beta-1a on brain magnetic resonance imaging (MRI) lesions, and no evidence of disease activity (NEDA; absence of clinical [relapses and 12-week confirmed disability progression] and MRI [gadolinium-enhancing, and new or newly-enlarging T2 hyperintense lesions] disease activity) during Year 1.RRMS patients (18-65 years; Expanded Disability Status Scale score ?5) were randomized to double-blind placebo or peginterferon beta-1a 125 ?g every 2 or 4 weeks. Sensitivity analyses of last observation carried forward and composite disease activity (using minimal MRI allowance definitions) were conducted.1512 patients were randomized and dosed (placebo n?=?500; peginterferon beta-1a every 2 [n?=?512] or 4 [n?=?500] weeks). Every 2 week dosing significantly reduced, versus placebo and every 4 week dosing, the number of new or newly-enlarging T2 hyperintense lesions at Weeks 24 (by 61% and 51%, respectively) and 48 (secondary endpoint; by 67% and 54%, respectively); all p?

SUBMITTER: Arnold DL 

PROVIDER: S-EPMC4311432 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.

Arnold Douglas L DL   Calabresi Peter A PA   Kieseier Bernd C BC   Sheikh Sarah I SI   Deykin Aaron A   Zhu Ying Y   Liu Shifang S   You Xiaojun X   Sperling Bjoern B   Hung Serena S  

BMC neurology 20141231


<h4>Background</h4>Subcutaneous peginterferon beta-1a provided clinical benefits at Year 1 (placebo-controlled period) of the 2-Year Phase 3 ADVANCE study in relapsing-remitting multiple sclerosis (RRMS). Here we report the effect of peginterferon beta-1a on brain magnetic resonance imaging (MRI) lesions, and no evidence of disease activity (NEDA; absence of clinical [relapses and 12-week confirmed disability progression] and MRI [gadolinium-enhancing, and new or newly-enlarging T2 hyperintense  ...[more]

Similar Datasets

| S-EPMC5400156 | biostudies-literature
| S-EPMC5301356 | biostudies-literature
| S-EPMC4345961 | biostudies-literature
| S-EPMC4512519 | biostudies-literature
| S-EPMC4954841 | biostudies-literature
| S-EPMC5010838 | biostudies-literature
| S-EPMC5516189 | biostudies-literature
| S-EPMC6113734 | biostudies-literature
| S-EPMC4645170 | biostudies-literature
| S-EPMC5794695 | biostudies-other